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ACCELERATED APPEARANCE OF NEOPLASMS IN 
FEMALE NZB/NZW MICE TREATED WITH 
HIGH-DOSE CYCLOPHOSPHAMIDE 
SARA E. WALKER and MIRIAM R. ANVER 
Prolonged immunosuppressive therapy with cy- 
clophosphamide increases the prevalence of neoplasms 
in NZB/NZW mice, an animal model of systemic lupus 
erythematosus. The current study was designed to com- 
pare the oncogenic properties of high dose cyclophos- 
phamide with a low dose therapeutic regimen. Female 
NZB/NZW mice received life-long therapy with “high 
dose” cyclophosphamide, 16 mg/kg/day, or “low dose” 
cyclophosphamide, 5.7 mg/kg/day; control mice re- 
ceived saline. High dose therapy clearly accelerated a p  
pearance of neoplasms. Seventeen of 19 mice treated 
with highdose cyclophosphamide developed neoplasms 
at the mean age of 61 weeks. Fifty-seven percent of 
these tumors were mammary carcinomas. Neoplasms 
appeared in all mice treated with low dose; mean longev- 
ity in this treatment group was 80 weeks (compared to 
high dose treated mice, P < 0.001). Carcinomas, pulmo- 
nary adenomas, and lymphomas were the most common 
tumors in mice receiving low dose therapy. Positive 
tests for ANA were suppressed in high dose treated 
mice. AntiDNA antibody levels and glomerulonephritis 
were decreased significantly in both groups of cyclo- 
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phosphamide-treated mice compared to controls. It was 
concluded tha t  the  high daily dose of immuno- 
suppressive drug was related to early oncogenesis in au- 
toimmune NZB/NZW mice. 
Hybrid New Zealand Black/New Zealand 
White (NZB/NZW) mice spontaneously develop heter- 
ogeneous antinuclear antibodies detected by indirect 
immunofluorescence (ANA) ( l), specific antibodies to 
DNA (antiDNA) (2), and immune complex glomerulo- 
nephritis (3). Disease is accelerated in females, and 50% 
of female NZB/NZW mice die with renal failure at 10 
months of age (1). These animals are accepted as mod- 
els of systemic lupus erythematosus (SLE). Early exper- 
iments in this laboratory showed that long-term treat- 
ment with the potent immunosuppressive drug 
cyclophosphamide effectively suppressed antiDNA, pre- 
vented glomerulonephritis, and prolonged lifespans in 
female NZB/NZW mice. Ninety-four percent of mice 
receiving cyclophosphamide, 8 mg/kg/day, developed 
neoplasms. Only 9% of untreated control mice died with 
malignancies. Neoplasms appeared in mice receiving 
therapy with cyclophosphamide for periods mngipg 
from 30 to 93 weeks (4). The high incidence of malig- 
nancies in these old mice suggested that cyclophospha- 
mide caused neoplastic transformation in treated ani- 
mals. However, it may be argued that NZB/NZW mice 
developed neoplasms as a consequence of aging after 
their lives were prolonged artificially by immuno- 
suppressive treatment. 
In the current study, additional groups of NZB/ 
NZW mice received life-long therapy with “low dose” 
cyclophosphamide, 5.7 mg/kg/day, or “high dose” cy- 
clophosphamide, 16 mg/kg/day; control mice received 
saline. If neoplasms were associated with aging in New 
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Table 1. Comparison of neoplasms in NZB/NZW mice treated with cyclophosphamide 
Mice with Classification of neoplasms 
neoplasia/ Mice with 
total mice multiple Total Mammary Other Pulmonary Other 
Therapy in group neoplasms neoplasms Lymphomas carcinomas carcinomas adenomas Sarcomas neoplasms 
Cy, 16 mg/kg/day 17/19' 8 28 2 16 4 0 6 0 
Cy, 5.1 rng/kg/day 15/15' I 1  27 6 5 3 1 4 2 t  
* Mice dying of iatrogenic causes or lost because of autolysis were excluded from this table. 
t Cutaneous histiocytoma ( I ) ,  chondroma ( I ) .  
Zealand mice with lives extended by therapy, tumors 
would appear in both high dose and low dose treatment 
groups after prolonged exposure to cyclophosphamide. 
On the other hand, if cyclophosphamide were onco- 
genic, neoplasms might appear earlier in mice treated 
with the larger dose of cyclophosphamide. The signifi- 
cantly earlier appearance of tumors in high dose treated 
mice compared to low dose treated mice supported the 
concept that cyclophosphamide has oncogenic proper- 
ties in NZB/NZW mice. 
MATERIALS AND METHODS 
Animals. Breeding and maintenance of New Zealand 
Black (NZB), New Zealand White (NZW), and NZB/NZW 
mice in the Rackham Arthritis Research Unit were described 
in another publication (4). 
Treatment protocol. Cyclophosphamide (Mead John- 
son and Co., Evansville, Indiana) was dissolved in sterile 
0.15M NaCl immediately before use and given by subcutane- 
ous injection to 2 groups of female NZB/NZW mice. Twenty- 
one mice (mean age 9 weeks f 0.1) were injected wih cyclo- 
phosphamide, 16 mg/kg/day. Seventeen mice with a mean 
age of 7 weeks (z t  0.4 SE) received cyclophosphamide, 5.7 
mg/kg/ day. Fifteen female control mice (mean age 11 weeks 
k I )  received daily injections of 0.1 ml 0.15M NaC1. All 3 
groups of mice were treated until death. 
Results of therapy in mice treated with the small dose 
of cyclophosphamide and in control mice were reported else- 
where (5 ) .  These animals are included here to permit com- 
parison with the 16 mg/kg/day treatment group. Control 
mice were entered into the study 8 months after treatment was 
started in the 5.7 mg/kg/day treatment group. Six months 
later the 16 mg/kg/day treatment group was established. Be- 
cause of the increased longevity in mice receiving low-dose 
cyclophosphamide, 94% of these animals were alive when sa- 
line injections were started in the control mice. Therefore, 
lifespans overlapped in all 3 groups of mice. 
Procedures. Mice were bled by puncture of the orbital 
plexus before treatment began and after 24 and 52 weeks of 
therapy. Terminal blood samples were obtained from 49 ani- 
mals. Sera were stored in sealed capillary tubes at -2OOC. 
Mice were examined daily. They were killed when they were 
moribund or when they developed neoplasms. Complete au- 
topsies were performed and tissue was processed, stained, and 
examined by light microscopy using methods described in ear- 
lier publications from this laboratory (4,6). Renal disease was 
scored by counting numbers of specific histologic abnormal- 
ities in 20 glomeruli in a 4p section from each kidney (7,8). 
The presence of arteritis was recorded, and periarterial lym- 
phocyte collections were graded on a scale of 0 to 4+: 0 = no 
lymphocytes, I+ = few lymphocytes, 2+ = lymphocytes sur- 
rounded 50% of arterial wall, 3+ = lymphocytes surrounded 
75% of arterial wall, 4+ = lymphocytes surrounded entire ar- 
tery. 
Autoantibodies. Heterogeneous ANA were detected in 
undiluted mouse serum tested on human leukocyte substrate 
(9). AntiDNA antibodies were measured using a modified 
Farr assay; values greater than 20% binding indicated the 
presence of an abnormal amount of antiDNA (9). 
Statistical analysis. Student's t test and xz analysis 
were calculated as described by Snedecor and Cochran (10). 
RESULTS 
Longevity. Two mice from each treatment group 
and 2 mice from the control group died of iatrogenic 
causes or were lost because of autolysis. These 6 ani- 
mals were not included in descriptions of longevity, 
neoplasms, and renal pathology. 
The mean age at death in control mice was 46 
weeks f 4; one untreated mouse survived to 77 weeks of 
age. Lifespans were prolonged significantly in cyclo- 
phosphamide-treated mice compared to control mice. In 
the 16 mg/kg/day treatment group, the mean age at 
death was 59 weeks f 2 (P < 0.005). In the group 
treated with cyclophosphamide, 5.7 mg/kg/day, mean 
longevity was 80 weeks f 3 weeks. Mice in the high 
dose treatment group had significantly decreased mean 
lifespan compared to mice treated with the low dose of 
cyclophosphamide (P < 0.001). The early deaths in high 
dose treated mice reflected premature appearance of 
neoplasms. 
Causes of death. All 13 control mice that were 
followed until spontaneous death had vasculitis and se- 
vere proliferative glomerulonephritis. These lesions are 
characteristically present in untreated NZB/NZW mice 
(1). Control mice did not have neoplasms. 
Table 1 lists the results of postmortem examina- 
tions in treated mice. Neoplasms were found in 17 of 
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Figure 1. Cumulative deaths in 47 cyclophosphamide-treated and 
control mice are illustrated in this graph. Six mice dying of iatrogenic 
causes or lost by autolysis were excluded. Mean lifespans in each 
group of treated mice were prolonged significantly compared to con- 
trol mice. Mice receiving the higher dose of cyclophosphamide (16 
mg/kg/day) had accelerated appearance of neoplasms and died ear- 
lier compared to mice treated with cyclophosphamide, 5.7 mg/kg/ 
day. 
the 19 mice that were not lost by iatrogenic death or 
autolysis in the 16 mg/kg/day treatment group. Mul- 
tiple neoplasms appeared in 8 mice. A total of 28 neo- 
plasms were found in mice receiving the larger dose of 
cyclophosphamide. One mouse died with pneumonia, 
and one mouse had extensive liver infarcts. All 15 mice 
that were treated with cyclophosphamide, 5.7 mg/kg/ 
day until death, died with malignant neoplasms or were 
killed when tumors were found by physical examina- 
tion. Eleven of these mice had more than one neoplasm, 
and a total of 27 neoplasms were identified in the 15 
mice in this treatment group. High dose cyclophospha- 
mide therapy accelerated oncogenesis in NZB/NZW 
mice. High dose mice were treated for a mean period of 
50 weeks A 2 before neoplasms caused death. This pe- 
riod was increased significantly compared to low dose 
treated mice, whose mean duration of therapy was 73 
weeks f 3 (P < 0.001). 
Early mortality, reflecting accelerated appear- 
ance of neoplasms in the 16 mg/kg/day treatment 
group, is illustrated in Figure 1. The first neoplasms in a 
high dose treated mouse were found after 26 weeks of 
therapy in an animal with pulmonary adenocarcinoma 
and squamous cell carcinoma of the bladder. One half 
of the mice in this group died with neoplasms by the 
forty-ninth week of treatment; the last survivors devel- 
oped tumors after 65 weeks of therapy. The first mouse 
in the low dose treatment group to develop a neoplasm 
died with a reticulum cell sarcoma after 35 weeks of 
treatment. Fifty percent of mice receiving cyclophos- 
phamide, 5.7 mg/kg/day, were dead with neoplasms in 
the seventy-second week of treatment. The oldest mouse 
in this treatment group died after 96 weeks of therapy. 
Another characteristic that differentiated mice in 
the high dose treatment group from low dose treated 
mice was the classification of neoplasms (Table 1). Two 
lymphomas appeared in the high dose treatment group. 
Sixteen mammary carcinomas were found in this treat- 
ment group; 4 additional carcinomas involved bladder 
or vulva. Pulmonary adenomas were not identified in 
high dose treated mice. In contrast, 6 mice that were 
treated with low dose cyclophosphamide developed ma- 
lignant lymphomas. Eight carcinomas, 7 pulmonary 
adenomas, 4 sarcomas, one local histiocytoma, and one 
chondroma were identified. 
Cumulative doses of cyclophosphamide. Total 
doses of cyclophosphamide given to mice with lym- 
phomas and other neoplasms are listed in Table 2. High 
dose therapy with cyclophosphamide, 16 mg/kg/day, 
was associated with two lymphomas. These malig- 
nancies appeared in mice that received total doses of 
158 and 16 1 mg of cyclophosphamide during 47 and 48 
weeks of treatment. In mice treated with cyclophospha- 
mide, 5.7 mg/kg/day, 6 lymphomas appeared after a 
mean treatment period of 62 weeks. The mean cumula- 
tive dose of drug in these mice was 74 mg. Other neo- 
plasms in this treatment group appeared after a mean 
treatment period of 76 weeks, wherein the mice received 
a mean total cyclophosphamide dose of 90 mg. 
Antinuclear antibodies. After 24 weeks of treat- 
Table 2. Cumulative doses of cyclophosphamide in NZB/NZW mice 
Lymphomas Other neoplasms 
Duration Total dose Duration Total dose 
Therapy (WW (mg) (wks) (mg) 
CY, 16 mg/kg/day 47,48 158, 161 47 (26-65); 168 (87-218) 
CY, 5.7 mg/kg/day 62 (35-76) 74 (42-90) 76 (60-96) 90 (7 1-1 14) 
* Mean. Parentheses enclose range. 
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Table 3. Autoantibodies in control and cyclophosphamide-treated NZB/NZW mice 
Therapy 
Weeks of treatment* 
0 24 52 Terminal 
A NA 
Controls 
CY, 16 mg/kg/day 
CY, 5.7 mg/kg/day 
AntiDNA 
Controls 
CY, 16 mg/kg/day 
CY, 5.7 mg/kg/day 
5/15 
(33) 
15/19 
(79) 
11/20 
( 5 5 )  
16 f 0.6$ 
24 f 1 
13 f 0.4 
* Numbers of mice with positive indirect immunofluorescent tests for heterogeneous ANA/number of 
mice tested. Parentheses enclose percent of mice with positive tests at each bleeding point. 
t Compared to control mice, P < 0.005. * Mean f SE. A modified Farr technique was used to test sera for antiDNA. Values are expressed as per- 
cent of ''C-labeled DNA bound to 0.15 ml of mouse serum. 
Q Compared to control mice, P < 0.005. 
ment, ANA tests were positive in 100% of control mice 
and 90% of low dose treated mice (Table 3). In high 
dose treated animals, 37% of mice were ANA-positive 
after 24 weeks of therapy; the incidence of positive tests 
was decreased significantly compared to controls (P c 
0.005). 
AntiDNA antibodies. In control mice, mean anti- 
DNA levels increased from 16% to 38% in the first 24 
weeks of the study (Table 3). In mice treated with cyclo- 
phosphamide, 16 mg/kg/day, mean antiDNA values 
decreased from 24% to 16% during 52 weeks of therapy. 
Mean antiDNA values in mice treated with cyclophos- 
phamide, 5.7 mg/kg/day, were 16% after 24 weeks of 
therapy and 22% after 52 weeks of treatment. Cyclo- 
phosphamide-induced suppression of antiDNA was evi- 
dent in both groups of treated mice after the first 24- 
week period of treatment. At this point, mean antiDNA 
levels in high dose (P < 0.001) and low dose (P c 0.001) 
treatment groups were decreased significantly compared 
to control mice. 
Renal lesions. Glomerular abnormalities in con- 
trol and treated mice are listed in Table 4. Severe prolif- 
erative glomerulonephritis in control animals caused the 
mean glomerular lesion count of 53 f 2. Renal arteritis 
was found in 9 of 13 control mice. Significantly lower 
mean glomerular lesion counts and the absence of arte- 
ritis in both groups of treated mice reflected the pro- 
tective effect of cyclophosphamide therapy. In mice that 
received the high dose of cyclophosphamide, the mean 
glomerular lesion count was 14 f 1. The mean glomeru- 
lar lesion count in mice treated with low dose cyclo- 
phosphamide was 21 f 2. 
DISCUSSION 
The use of cytotoxic drugs to treat patients with 
inflammatory diseases of connective tissue has raised 
the important question of whether these patients are at 
increased risk to develop neoplasms. To gather addi- 
tional information pertaining to tumor occurrence in 
immunosuppressive therapy of autoimmune disease, an 
ongoing project in this laboratory has examined neo- 
plasia in NZB/NZW mice receiving the alkylating 
agent cyclophosphamide. Female NZB/NZW mice 
were chosen for this study because their autoimmune 
disease is analogous to SLE in humans (3). 
Early therapeutic studies reported by Russell 
and Hicks showed that cyclophosphamide treatment 
was associated with neoplasms in 29% of female NZB/ 
NZW mice in the long-term treatment group (1 1). Ad- 
ditional experiments in this laboratory verified the on- 
cogenic potential of cyclophosphamide in hybrid New 
Zealand mice. Lifelong treatment of NZB/NZW mice 
with cyclophosphamide, 8 mg/kg/day, suppressed anti- 
DNA and prevented development of severe glomerulo- 
Table 4. Glomerular lesions and renal arteritis in control and 
cyclophosphamide-treated NZB/NZW mice 
Glomerular 
Arteritis 
Controls (saline only) 53 f 2' 9/13t 
Cy, 16 mg/kg/day 14 f I* 0/19 
CY, 5.7 mg/kg/day 21 f 2 *  0/15 
* Mean f SE. Lesions were counted in 20 glomeruli in a 4p section of 
renal tissue. 
t Number of kidneys with arteritis/number of kidneys examined. * Compared to control mice, P < 0.001. 
Therapy lesions 
1342 WALKER AND ANVER 
nephritis (9). Lifespans were prolonged significantly in 
treated female mice; mean longevity in this group was 
77 weeks compared to longevity of 51 weeks in female 
control mice (P = 0.0005). Neoplasms arose in 100% of 
treated females, compared to tumor incidence of 6% in 
control female mice (4). The increased incidence of neo- 
plasms in cyclophosphamide-treated mice was con- 
firmed by other investigators (12,13). 
Untreated NZB/NZW mice have a low back- 
ground incidence of malignancy (43). However, these 
animals may succumb to autoimmune disease at an 
early age before neoplasms appear. The appearance of 
neoplasms in NZB/NZW mice with lives prolonged by 
cyclophosphamide therapy may have resulted from age- 
related changes in immunologic response. NZB/NZW 
mice lose T-cell function after the age of 18 weeks (14), 
and old mice lack an important immunologic defense 
mechanism that might protect them from developing 
cancer. Furthermore, New Zealand mice carry type C 
viruses capable of inducing lymphomas or sarcomas. In- 
jections of murine leukemia virus obtained from NZB 
lymphoblasts resulted in formation of lymphomas in ge- 
netically susceptible BALB/c x NZB F, hybrid mice 
(15). In another study, budding type C viral particles 
were identified in a sarcoma that arose spontaneously in 
an untreated NZB/NZW mouse. Inoculation of this po- 
tent virus produced rapid development of tumors in 
BALB/c mice, rats, and hamsters (16). It is postulated 
that type C viruses proliferate and induce neoplasms in 
old mice with age-related suppression of protective im- 
mune systems. 
In this laboratory therapeutic experiments with 
hydrocortisone showed that neoplasia was an important 
consequence of prolonged therapy of New Zealand 
mouse disease. Female NZB/NZW mice treated with 
hydrocortisone sodium succinate, 10 mg/kg/day, had 
extreme prolongation of life which exceeded lifespans in 
cyclophosphamide-treated mice. AntiDNA antibodies 
were produced throughout the first year of treatment, 
and delayed onset of renal insufficiency appeared to re- 
sult from the potent antiinflammatory action of hydro- 
cortisone. Neoplasms arose in 76% of hydrocortisone- 
treated mice. The pattern of oncogenesis in mice treated 
with corticosteroids differed from that in cyclophospha- 
mide-treated mice. Fifty-three percent of the neoplasms 
in mice treated with hydrocortisone were sarcomas. Al- 
though this study did not separate the effects of aging 
from possible oncogenic effects of prolonged corticoste- 
roid therapy, it supported the theory that tumors are 
common in aged, treated female NZB/NZW mice (6). 
Other studies have shown that cyclophospha- 
mide is carcinogenic in both mice and rats. When A 
strain mice were treated with cyclophosphamide, 5 mg/ 
kg/day, twice a week for 15 weeks, tumors were found 
in 38% of treated mice compared to 18% of control mice 
( 17). Furthermore, cyclophosphamide therapy is associ- 
ated with damaged bladder epithelium in mice (18) and 
bladder neoplasms in rats. Fischer rats treated with the 
bladder carcinogen, N-2-fluorenylacetamide, received a 
single intraperitoneal injection of cyclophosphamide 
followed by a pyridoxine-deficient diet. These animals 
had accelerated appearance of bladder carcinomas and 
a higher incidence of carcinomas compared to rats 
treated with the carcinogen and deficient diet alone 
The theory that cyclophosphamide therapy is di- 
rectly responsible for tumor genesis in NZB/NZW mice 
is supported by results of treating male New Zealand 
mice in this laboratory. In male NZB/NZW mice re- 
ceiving lifelong treatment with cyclophosphamide, 8 
mg/kg/day, autoimmune disease was suppressed but 
lifespans were not prolonged. Mean longevity was 90 
weeks in treated males and 76 weeks in control males 
(P = 0.08). Nevertheless, tumors arose in 89% of treated 
male mice compared to a significantly lower tumor in- 
cidence of 13% in untreated male mice (P = 0.003) (4). 
Hahn and associates have reported that cyclophospha- 
mide is more oncogenic than azathioprine in New 
Zealand mice. NZB/NZW mice received long-term 
treatment with cyclophosphamide or azathioprine-plus- 
prednisolone and lifespans were prolonged in both 
groups of mice. Neoplasms were found in 61% of cyclo- 
phosphamide-treated mice. In contrast, none of the 
mice that received azathioprine-plus-prednisolone de- 
veloped neoplasms (12). 
Sullins and associates studied neoplasia in NZB/ 
NZW mice treated with 3 doses of cyclophosphamide- 
1.5, 3.5, and 12 mg/kg/day. Incidences of lymphomas in 
each treatment group were 1796, 40%, and 89% respec- 
tively. The incidence of other neoplasms was not re- 
corded. Although numbers of lymphomas increased 
with size of the daily dose of cyclophosphamide, there 
was no correlation between incidence of lymphomas 
and cumulative dose of drug or number of weeks in the 
treatment period (20). The current study confirmed the 
finding that lymphomas were not associated with total 
dose of cyclophosphamide or duration of therapy. How- 
ever, we found that mammary carcinomas were the 
most common neoplasm in mice receiving the higher 
dose of immunosuppressive drug. The different in- 
(19)- 
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cidence of lymphomas versus carcinomas in the two 
studies is not readily explained. Mice bearing localized 
mammary tumors might have developed lymphomas at 
a later time if they had continued treatment. 
In summary, extended therapeutic studies have 
shown that oncogenesis in New Zealand mice is acceler- 
ated by prolonged treatment with large daily doses of 
cyclophosphamide. Cyclophosphamide is the most on- 
cogenic immunosuppressive drug in NZB/NZW mice; 
hydrocortisone therapy is associated with a smaller 
number of neoplasms. The pattern of oncogenesis in cy- 
clophosphamide-treated mice is influenced by the daily 
dose of drug. Earlier studies in this laboratory showed 
that a very low dose of cyclophosphamide, 1.5 mg/kg/ 
day, did not suppress autoimmune disease in NZB/ 
NZW mice. This ineffective dose also failed to produce 
neoplasms. Mice receiving larger doses (5.7 and 8 mg/ 
kg/day) were protected from antiDNA antibodies and 
glomerulonephritis. Nevertheless, these immuno- 
suppressed animals had a high incidence of neoplasms 
(4). In the current study, a very large daily dose of cy- 
clophosphamide ( 16 mg/kg/day) accelerated the ap- 
pearance of neoplasms. This finding confirms the onco- 
genic properties of cyclophosphamide in NZB/NZW 
mice. 
ACKNOWLEDGMENTS 
The authors thank Ms Barbara Boddy and Ms Cheryl 
Hassett for excellent technical assistance. 
REFERENCES 
1. 
2. 
3. 
4. 
5. 
6 .  
Howie JB, Helyer BJ: The immunology and pathology of 
NZB mice. Adv Immunol9:215-266, 1968 
Steinberg AD, Pincus T, Tala1 N: DNA-binding assay for 
detection of antiDNA antibodies in NZB/NZW F, mice. 
J Immunol 102:788-790, 1969 
Lambert PH, Dixon FJ: Pathogenesis of the glomerulone- 
phritis of NZB/W mice. J Exp Med 127:507-521, 1968 
Walker SE, Bole GG Jr: Augmented incidence of neo- 
plasia in NZB/NZW mice treated with long-term cyclo- 
phosphamide. J Lab Clin Med 82:619-633, 1973 
Walker SE, Anver MR: Stimulated autoantibody re- 
sponse and increased longevity in NZB/NZW mice 
treated with cyclophosphamide and tilorone. Clin Exp 
Immunol33:453462, 1978 
Walker SE, Anver MR, Schechter SE, Bole GG: Pro- 
longed lifespan and high incidence of neoplasms in NZB/ 
NZW mice treated with hydrocortisone sodium succinate. 
Kidney Int 14:151-157, 1978 
7. Pirani CL, Pollak VE, Schwartz FD: The reproducibility 
of semiquantitative analyses of renal histology. Nephron 
1:230-237, 1964 
8. Walker SE, Bole G G  Jr: Influence of natural and syn- 
thetic estrogens on the course of autoimmune disease in 
the NZB/NZW mouse. Arthritis Rheum 16:23 1-239, 
1973 
9. Walker SE, Bole GG Jr: Selective suppression of autoan- 
tibody responses in NZB/NZW mice treated with long- 
term cyclophosphamide. Arthritis Rheum 18:265-272, 
1975 
10. Snedecor GW, Cochran WG: Statistical Methods. Sixth 
edition. Ames, Iowa, Iowa State University Press, 1967, 
pp 104-106,217 
1 1. Russell PJ, Hicks JD: Cyclophosphamide treatment of 
renal disease in (NZB/NZW) F, hybrid mice. Lancet 
1:440-446, 1968 
12. Hahn BH, Knotts L, Ng M, Hamilton TR: Influence of 
cyclophosphamide and other immunosuppressive drugs 
on immune disorders and neoplasia in NZB/NZW mice. 
Arthritis Rheum 18: 145-152, 1975 
13. Moms AD, Esterly J, Chase G, Sharp GC: Cyclophos- 
phamide protection in NZB/NZW disease: mechanisms 
and therapeutic regimens. Arthritis Rheum 19:49-55, 
1976 
14. Krakauer RS, Waldmann TA, Strober W Loss of sup- 
pressor T cells in adult NZB/NZW mice. J Exp Med 
15. Croker BP Jr, Del Villano BC, Jensen FC, Lerner RA, 
Dixon FJ: Immunopathogenicity and oncogenicity of mu- 
rine leukemia viruses. I. Induction of immunologic dis- 
ease and lymphoma in (BALB/c X NZB) F, mice by 
Scripps leukemia virus. J Exp Med 140: 1028-1048, 1974 
16. Gazdar AF, Chopra HC, Sarma PS: Properties of a mu- 
rine sarcoma virus isolated from a tumor arising in an 
NZB/NZW F, hybrid mouse. I. Isolation and pathology 
of tumors induced in rodents. Int J Cancer 9:219-233, 
1972 
17. Tokouka S: Induction of tumor in mice with N, N-bis(2- 
chloroethy1)-N’,o-propylenephosphoric acid ester diam- 
ide (cyclophosphamide). Gann 56:537-54 I ,  1965 
18. Campobasso 0, Berrino F: Early effects of cyclophospha- 
mide on mouse bladder epithelium. Pathol Microbiol (Ba- 
sel) 38:144-157, 1972 
19. Koss LG, Lavin P: Studies of experimental bladder carci- 
noma in Fischer 344 female rats. I. Induction of tumors 
with diet low in vitamin B, containing N-2-fluorenyla- 
cetamide after single dose of cyclophosphamide. J Natl 
Cancer Inst 46:585-592, 197 1 
20. Sullins D, Moms AD, Jones M, Buchert P, Moeschberger 
M: Effect of immunosuppressive regimen on oncogenesis 
in NZB/NZW autoimmune disease (abstract). Arthritis 
Rheum 21:596, 1978 
144:622-673, 1976 
